June 4, 2009
A Johnson & Johnson-run study found that its experimental drug TMC207 could make conventional tuberculosis treatment five times more effective against multi-drug resistant TB (MDR-TB) because it cleared traces of the TB bacteria in the sputum of 48 percent of study volunteers after eight weeks, Reuters reports (Emery, Reuters, 6/3). The results were published on Wednesday in the New England Journal of Medicine.
TMC207 was tested in a Phase 2 trial of 47 South African patients with newly diagnosed MDR-TB, the Dow Jones Newswires/Wall Street Journal reports. "About half received TMC207 and the rest received a fake drug for about eight weeks; all patients took a standard regimen of five existing TB drugs. A higher proportion of patients who received TMC207 tested negative for TB in lung-fluid cultures at eight weeks than the placebo, 48 percent versus 9 percent," the Dow Jones Newswires/Wall Street Journal reports (Loftus, Dow Jones Newswires/Wall Street Journal, 6/3).
According to Reuters, TMC207 is "being billed as the first new TB drug in 40 years." David McNeeley of Tibotec Inc., the subsidiary of Johnson & Johnson that developed the drug, said that TMC207 differs from other TB drugs because it "starves" the bacteria. "It's like cutting off your food supply," he said (Reuters, 6/3).
NEJM published a second study that "describes an international effort to detect" TB in immigrants and refugees that come to the U.S., HealthDay News/Forbes reports. "The TB rate in [foreign-born individuals] is 9.8 times higher than among U.S.-born individuals -- 20.6 cases per 100,000 people versus 2.1 per 100,000 people for the native-born. Nearly 58 percent of the new TB cases in the United States in 2007 were diagnosed in the foreign-born group," according to HealthDay News/Forbes (HealthDay News/Forbes, 6/3).
Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2009 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.